C. Eder

发表

Landscape of TET2 mutations in acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

Chemokine Expression by Small Sputum Macrophages in COPD

I. Heimbeck, T. P. Hofer, L. Ziegler‐Heitbrock, 2011, Molecular medicine.

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Genetic mapping of sequence-specific PCR-based markers on the short arm of the 1BL.1RS wheat-rye translocation

T. Lelley, M. Molnár-Láng, C. Eder, 2003, Euphytica.

Somatic Mutations and Inborn Variants in Exon 12 of ASXL1 in Different Myeloid Neoplasms

H. Wichmann, N. Klopp, T. Illig, 2011 .

Standardized single‐platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females

I. Heimbeck, L. Ziegler‐Heitbrock, M. Frankenberger, 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance

A. Kohlmann, T. Haferlach, S. Schnittger, 2010 .

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis

T. Haferlach, W. Kern, C. Haferlach, 2019, International journal of laboratory hematology.

Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2009 .

Identification of the Arabidopsis thaliana Flavonoid 3'-Hydroxylase Gene and Functional Expression of the Encoded P450 Enzyme

B. Weisshaar, S. Martens, G. Forkmann, 2000, Biological chemistry.

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

The role of different genetic subtypes of CEBPA mutated AML

C Haferlach, A Kohlmann, T Haferlach, 2014, Leukemia.

CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, British journal of haematology.

Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Chronic Myeloproliferative Disorders

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Cloning, Functional Identification and Sequence Analysis of Flavonoid 3′-hydroxylase and Flavonoid 3′,5′-hydroxylase cDNAs Reveals Independent Evolution of Flavonoid 3′,5′-hydroxylase in the Asteraceae Family

S. Martens, Bettina Deiml, G. Forkmann, 2006, Plant Molecular Biology.

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

S. Ogawa, A. Kohlmann, T. Haferlach, 2012, Blood.

AFLP fingerprinting suggests an allopolyploid origin of two members of the Leucanthemum vulgare aggregate (Compositae, Anthemideae) in central Europe

R. Vogt, C. Oberprieler, C. Eder, 2011 .

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, PloS one.

Influence of 1BL.1RS wheat-rye chromosome translocation on genotype by environment interaction

T. Lelley, H. Grausgruber, C. Eder, 2004 .

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Blood Cancer Journal.

Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors

T. P. Hofer, C. Brightling, L. Kobzik, 2009, Journal of leukocyte biology.

A novel hierarchical prognostic model of AML solely based on molecular mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome

T. Haferlach, S. Schnittger, W. Kern, 2014, Leukemia.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

T. Haferlach, S. Schnittger, W. Kern, 2015, Leukemia research.

Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia

N. Schmitz, S. Schnittger, W. Kern, 2015 .

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

T. Haferlach, S. Schnittger, W. Kern, 2014, Leukemia.

Molecular analyses of 15 , 542 patients with suspected BCR-ABL 1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow by

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

N. Schmitz, N. Klopp, T. Illig, 2013, Leukemia.

Ultrafine carbon particles down-regulate CYP1B1 expression in human monocytes

K. Schramm, T. P. Hofer, F. Stanzel, 2009, Particle and Fibre Toxicology.

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML

A. Peters, T. Haferlach, S. Schnittger, 2015, Annals of Hematology.

A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.

T. Haferlach, S. Schnittger, W. Kern, 2011, Experimental hematology.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2015, Haematologica.

ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2011 .

Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

T. Haferlach, A. Borkhardt, S. Schnittger, 2014, Leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2011, Experimental Hematology.

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

Chemokine Expression by Small Sputum Macrophages in COPD

I. Heimbeck, W. Möller, M. Frankenberger, 2011, Molecular medicine.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Haematologica.

Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors

C. Brightling, L. Kobzik, J. Grigg, 2009, Journal of leukocyte biology.